



Stereotaxis Announces Expanded European Labeling for Navigation in the Pericardial Space

April 11, 2018

ST. LOUIS, April 11, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that navigation in the pericardial space has been added to the CE Mark of the Niobe[®] magnetic navigation system in Europe.

"We pursued this indication to further enhance our ability to help treat the most challenging arrhythmias," said David Fischel, Chairman and Chief Executive Officer. "The architectural superiority of Stereotaxis technology is particularly valuable in this type of procedure. Stereotaxis remains committed to enabling the safe and effective treatment of a broad range of arrhythmias including those that are difficult or impossible to treat with conventional approaches."

The pericardium is a fluid filled sac surrounding the heart. While cardiac ablation is typically performed on the endocardial surface from within the heart chambers, the cardiac tissue in the ventricles is sometimes too thick to allow for the creation of transmural lesions from the endocardial surface alone. There is growing recognition that epicardial ablation, ablation of the heart muscle from outside the heart in the pericardium, is valuable for more effective treatment of a broad range of complex arrhythmias. Navigation in the pericardial cavity entails unique challenges and conventional catheter technologies may not provide the reach and precision required to consistently be able to treat these arrhythmias.

"The *Niobe* system performs flawlessly during pericardial navigation," said Dr. Bruno Schwagten, MD, PhD, Middelheim Hospital, Antwerp, Belgium. "By directly manipulating the catheter tip, the *Niobe* system enables easy access to the whole pericardial area and allows the operator to visualize and target epicardial substrate in an unprecedented fashion."

"I appreciate the flexibility that using robotic magnetic navigation provides," said Professor Petr Neuzil, MD, PhD, FESC, Head of Department of Cardiology, Homolka Hospital, Prague, Czech Republic. "I don't need to be concerned with having a specific sheath or needing to choose whether to gain anterior or posterior access. I can use creative approaches to access hard-to-reach areas. Safety is also of great importance and catheter navigation with the *Niobe* system reduces the risk of adverse events versus other technologies."

About Stereotaxis

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis' systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Stereotaxis Contacts:

David Fischel
Chairman and Chief Executive Officer

Martin C. Stammer
Chief Financial Officer

314-678-6100
investors@stereotaxis.com



